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Abstract
Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration
using the well-established and safe combination of diethylcarbamazine and albendazole
(DA) since 2002. In certain settings the addition of ivermectin to this combination (IDA)
remains a safe strategy and is more efficacious. However, the safety has yet to be described
in scabies and soil-transmitted helminth endemic settings like Fiji. Villages of Rotuma and
Gau islands were randomised to either DA or IDA. Residents received weight-based treat-
ment unblinded with standard exclusions. Participants were actively found and asked by a
nurse about their health daily for the first two days and then asked to seek review for the
next five days if unwell. Anyone with severe symptoms were reviewed by a doctor and any
serious adverse event was reported to the Medical Monitor and Data Safety Monitoring
Board. Of 3612 enrolled and eligible participants, 1216 were randomised to DA and 2396 to
IDA. Age and sex in both groups were representative of the population. Over 99% (3598) of
participants completed 7 days follow-up. Adverse events were reported by 600 participants
(16.7%), distributed equally between treatment groups, with most graded as mild (93.2%).
There were three serious adverse events, all judged not attributable to treatment by an inde-
pendent medical monitor. Fatigue was the most common symptom reported by 8.5%, with
headache, dizziness, nausea and arthralgia being the next four most common symptoms.
Adverse events were more likely in participants with microfilaremia (43.2% versus 15.7%),
but adverse event frequency was not related to the presence of scabies or soil-transmitted
helminth infection. IDA has comparable safety to DA with the same frequency of adverse
events experienced following community mass drug administration. The presence of co-
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endemic infections did not increase adverse events. IDA can be used in community pro-
grams where preventative chemotherapy is needed for control of lymphatic filariasis and
other neglected tropical diseases.
Author summary
Lymphatic filariasis is a parasitic infection that is spread between humans by mosquitos.
The adult worms can live up to 6 years in humans causing chronic irreversible damage to
lymphatic vessels resulting in permanent limb swelling known as elephantiasis. The filari-
asis worm is susceptible to three different drugs: ivermectin, diethylcarbamazine and
albendazole. They have been used in two drug combinations globally in communities at
risk of filariasis infection, including Fiji, for over a decade. In an attempt to improve effi-
cacy of the treatment with the ultimate goal of eliminating the infection, the three drugs
are now being used in the one administration. In this study, the safety of the triple combi-
nation in Fiji was proven to be as safe as the standard two drug treatment. Two other com-
mon infections that will be affected by the new treatment, scabies and intestinal worms,
did not impact on the frequency of adverse events. The use of the triple combination in
Fiji has the potential to improve the control of common neglected diseases without excess
side effects.
Introduction
Lymphatic filariasis is caused by the parasitic, mosquito-borne filarial round-worm Wucher-
eria bancrofti and has been classified by the World Health Organization (WHO) as a neglected
tropical disease. The mosquito vector transmits the immature worms, known as microfilariae
(Mf), from human to human in 61 endemic countries. The WHO recommends mass drug
administration (MDA) for affected communities, as a key element of strategies to control and
ultimately eliminate lymphatic filariasis as a public health problem.[1]
Three anti-parasitic drugs, albendazole, diethylcarbamazine and ivermectin, have therapeu-
tic efficacy against lymphatic filariasis and so have been included by WHO in MDA recom-
mendations, with the specific choice of agents dependent on the presence of other endemic
pathogens.[2] The precise mechanism of action of these medications on the filarial worm are
not fully understood, but efficacy studies have determined macrofilaricidal and microfilarici-
dal activity when used in either two drug combination. The standard MDA in the Pacific is
based on the dual combination of diethylcarbamazine and albendazole (known together as
DA). Eleven countries, including Egypt, Thailand and Tonga, have achieved elimination tar-
gets and are under surveillance, but others, including eight countries in the Western Pacific
Region such as Samoa, Philippines and Fiji, have not done so despite multiple rounds of
MDA.[1]
Elephantiasis, one of the severe complications of lymphatic filariasis, was first reported
from Fiji in 1841, on the island of Rotuma [3], and a national survey in the 1940s observed a
Mf prevalence of 12.7%.[4] After limited success with vector control [5, 6], the Ministry of
Health commenced a national MDA with diethylcarbamazine in 1969.[7] In 1999, Fiji joined
the Pacific Programme to Eliminate Lymphatic Filariasis and delivered annual MDA from
2002 using DA. However, despite reportedly adequate DA treatment coverage above 65%, lym-
phatic filariasis has remained endemic in specific areas of Fiji.[1]
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Combining the three active agents into the one MDA combination, known as IDA, does
not create any drug-drug interactions, and is superior to DA in clearing microfilaremia at least
as long as 36 months after a single round of treatment.[8–10] With more effective filariasis
treatments it is expected that persons with microfilaremia will experience more adverse events
(AEs), attributable to the response to dead or dying parasites.[11, 12] This effect on AEs was
reported from a small efficacy trial based in Papua New Guinea.[8, 9] Fiji joined a 5-site inter-
national collaboration to examine the effect of IDA in a larger number of participants across
multiple geographic settings. This large global study of IDA confirmed more AEs occurred,
but the majority were mild and transient, and that this combination was a safe strategy for
community control of filariasis.[13, 14]
Ivermectin is also efficacious against two other neglected tropical diseases endemic in Fiji,
scabies and soil-transmitted helminths (STH).[2, 15–18] A national survey of scabies in 2007
found that all age groups and regions of Fiji are affected, with an estimated national prevalence
of 18.5%.[16, 19] Soil-transmitted helminths are also common in Fiji with a prevalence as high
as 45% in school-aged children.[20–22] Because the medications in the IDA drug combination
have activity against scabies and STH in addition to lymphatic filariasis, MDA with IDA repre-
sents an integrated intervention against three neglected tropical diseases. Successful treatment
of scabies and STH is expected to induce mild and transient symptoms primarily pruritus (sca-
bies) and abdominal pain (STH).[16, 18] We aimed to evaluate the safety of IDA in Fiji, pro-
viding a detailed account of AEs following DA and IDA mass drug administration in Fiji and
an analysis of factors associated with their occurrence including filariasis, scabies, and STH
infections.
Methods
We conducted a cluster randomised trial to compare the safety of MDA with DA and IDA.
We chose a cluster randomised design because the intervention is implemented at the commu-
nity level. The study procedures as applied to individuals were consistent with the protocol of
the multi-site safety trial of IDA (S1 Protocol).[13]
Ethical approvals, trial registration and oversight
Relevant government ministries and district offices in Fiji approved the engagement of com-
munities on these islands. The protocol was reviewed by the Royal Children’s Hospital Mel-
bourne Human Research Ethics Committee (reference 36205) and Fiji National Health
Research and Ethics Review Committee (reference 2016.81.MC). The trial was registered
(Clinitrials.gov NCT03177993 and ANZCTR N12617000738325). An independent Data Safety
Monitoring Board of six experts reviewed the protocol and met periodically throughout the
study to review reports.
Setting
The study was conducted in Fiji, an island nation in the Southwest Pacific with a population in
the most recent census (2017) of 884,887, a median age of 27.5 years and with 56% located in
urban settings.[23] People are predominantly of Melanesian, Polynesian or Indian descent.
There are four governmental divisions: Central, Northern, Eastern, and Western.
The Eastern Division was chosen for the study because it has the highest Mf prevalence in
the country of 2.2% in 2007. [24] Two of the divisions islands from this region, Rotuma and
Gau, were selected study sites. Both had previously received at least 10 rounds of MDA and,
based on filarial antigen prevalence, were due for a further round in 2017.[25] The islands met
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other criteria for being study sites, including having reliable communications, a hospital, and
an airstrip for medical evacuation.
Trial design
Villages were designated as clusters. All 35 villages on the two islands agreed to participate in
this study prior to randomisation. An independent statistician generated randomised treat-
ment allocation using Stata software in a 1:1:1 ratio stratified by island to either DA, IDA1
(ivermectin administered with diethylcarbamazine and albendazole) or IDA2 (same as IDA1,
plus a second dose of ivermectin on day 8). The IDA2 group was included to evaluate the com-
munity effectiveness of one versus two doses of ivermectin not reported here. Our study design
differed from the global study by including all community members regardless of eligibility for
LF treatment in order to allow community assessments for all three infections at both time-
points. For the purpose of analysing the safety of IDA up to 7 days, the IDA1 and IDA2 groups
were identical, so they were combined for safety analyses.
Treatments
Albendazole was provided as a fixed oral dose of 400mg. Diethylcarbamazine and ivermectin
were dosed according to weight and whole tablet ranges, aiming for 6mg/kg and 200μg/kg
respectively, (S1 Table). Participants and assessors were unblinded to treatment given.
Participants were excluded from receiving either IDA or DA treatment if they were less
than 2 years of age or 15 kg in weight, were pregnant, breastfeeding within 7 days of delivery,
or known to have a severe illness or allergy to study drugs. All women of child-bearing age
were asked on the timing of their last menses. If menses was more than 4 weeks or unknown, a
urine pregnancy test was offered. No contraceptive measures were provided or recommended,
consistent with WHO policy for LF MDA. Additionally, those in villages allocated to IDA
were excluded from taking ivermectin if aged less than 5 years. Topical permethrin cream 5%,
which is active against scabies, was provided to all individuals excluded from taking ivermec-
tin. It was also offered to individuals in the DA group identified at baseline screening as having
scabies and to their household contacts (S1 Fig).
All oral medication was taken under direct observation by a study team member. Permeth-
rin application was not observed. Instructions to adults in affected households recommended
permethrin to be applied over the whole body for 8 hours overnight (4 hours for children less
than 2 months of age) before washing off.
Community engagement and enrolment
Prior to enrolment there was extensive community engagement in each village including liai-
son with leaders and health representatives, and an interactive presentation. This introduced
and explained the study, the treatment group to which their village had been allocated,
expected date of enrolment, and the different procedures on enrolment day: individual con-
sent, screening for infections and administration of study medications. Anyone living in the
village at the time of MDA was invited to the community central meeting place to enrol
regardless of eligibility for MDA. Outreach visits to homes were conducted to allow people
with poor mobility to participate. Participants 13 years and older were asked to provide written
consent. Parental/guardian consent was required for all people aged less than 18 years and for
adults without capacity to consent. For individuals 13–17 years dual consent was required.
Written material was provided in English and the Fijian language, iTaukei, and staff members
provided verbal translation in iTaukei and Rotuman as required. Representatives from each
PLOS NEGLECTED TROPICAL DISEASES Safety of triple drug therapy for neglected tropical diseases
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village assisted the study team in creating up-to-date lists of village residents by household and
reasons for non-participation: temporarily away or declined.
Safety assessments
The primary outcome of safety of IDA was evaluated at the individual and cluster levels. A
training package from the global study [13] was provided to all staff to ensure consistency of
reporting between staff and across sites. Safety was assessed in two periods, consistent with the
timing of AEs observed in previous studies.[8–11] Active follow-up of all participants occurred
daily in the first two days following treatment, when more severe symptoms are expected with
death of microfilariae.[11] For continuity, participants were seen by the same nurse on the day
of taking tablets and day 1 and day 2 afterwards, and asked a standard open-ended question
about their health. During days 3 to 7 after treatment, monitoring comprised of two activities:
1) participants were asked to notify a study representative if they were unwell and required
assessment, and 2) participants previously identified as having an AE judged moderate or
worse were assessed each day, with assessments only stopping if symptoms improved to mild
severity or resolved completely (S2 Fig).
Symptoms were classified using terms from Medical Dictionary for Regulatory Activities
[26], and were graded based on the impact on daily activities of the participant: from mild (no
impact); moderate (unable to engage in normal functional activities like work or school);
severe (unable to undertake personal activities of daily living); or life-threatening (S2 Table).
[27] Further, participants identified with an AE judged moderate or worse had vital signs
taken by the study nurse. Participants with events graded as severe or life-threatening, or
graded as moderate with abnormal vital signs, symptoms of unclear cause or generating nurse
concern, were reviewed by a local doctor for full examination, management and assessment of
whether the event met the criteria for a serious AE (S2 Fig).
A serious AE was defined as one resulting in at least one of the following outcomes: death,
life-threatening event, new or prolongation of a hospital admission, persistent or significant
disability/incapacity, congenital anomaly, or other serious health event requiring medical
intervention to prevent one of the other outcomes listed above. All serious AEs were discussed
with the Medical Monitor, an offsite independent senior doctor trained in safety reporting.
The Global Medical Monitor reviewed all serious AE reports before they were reported to the
Data Safety Monitoring Board, ethics committees and medication suppliers.
Parasitology assessments
Participants were tested at baseline for the presence of parasitic infections known to be sensi-
tive to one or more of the study drugs. From an efficacy perspective, this testing would serve as
a baseline for subsequent assessments. From a safety perspective, it was important to be able to
relate potential effects of co-infection on drug efficacy and AEs.
Lymphatic filariasis. The prevalence of filarial infection was determined by two standard
methods. Circulating filarial antigen (CFA) was detected by placing approximately 75 μl of
capillary blood onto the rapid diagnostic test, Alere Filariasis Test Strip (FTS, Alere Scarbor-
ough, Inc., Scarborough, ME, USA). The CFA was quantified by comparing the colour
strength of the test strip against the control line at 10 minutes, scored as: CFA1 (weak positive);
CFA2 (medium positive); and CFA3 (strong positive).[28] The second method detects active
infection with W. bancrofti by light microscopy for Mf in a 60 μl stained capillary blood smear.
Mf testing was only performed for participants with a positive CFA result only. Each blood
smear was read independently by two laboratory technicians.[29, 30]
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Scabies. Scabies was diagnosed by trained nurses by identifying pruritic inflammatory
papules in a typical distribution.[31]
Soil-transmitted helminths. Stool pots and collection kits were distributed to the com-
munity prior to enrolment, and participants asked to bring in fresh stool on the day of enrol-
ment, and prior to administration of study drug. Stool was processed by the Kato-Katz
method within 12 hours of collection.[32] Smears were prepared in duplicate with each one
read independently by one of two trained laboratory technicians. A stool sample was consid-
ered positive if either technician identified eggs of Ascaris, Trichuris or hookworm.
Data management
Data were captured in real time into an electronic data capture system developed specifically
for the Fiji trial site by CliniOps (Fremont, CA, USA). The system allowed study team mem-
bers to enter de-identified information at enrolment for each participant, and linked informa-
tion collected at subsequent visits to the participant’s record.
Statistical methods
We reported our results consistent with Consolidated Standards of Reporting Trials (CON-
SORT) recommendations for cluster trials (S3 Table).[33, 34] Data were analysed as prospec-
tively planned and in accordance with International Conference on Harmonisation Statistical
Principles for Clinical Trials Guideline E9. A statistical analysis plan was written for the main
study and followed for the Fiji study. The Fiji site differs from the global study analysis by
including children aged 2–4 years who received LF treatment with DA according to WHO
guidelines. We described AEs by absolute number, severity, symptoms, treatment group,
island, sex, age-group and parasitological status at baseline. We used logistic regression
adjusted for clustering by village and stratification by island for statistical significance. We
compared AEs between subgroups in univariate and multivariate generalised linear models,
adjusting for clustering by village and stratification by island. We did not include STH results
in the multivariate analysis due to the low number of processed samples. Filariasis infection
was represented only by Mf results for the multivariate analysis. For sub-group analyses with
small denominators, statistical significance has been determined using Fischer’s exact test
without any adjustment for village clustering or island stratification.
Sample size. Fiji was part of a multi-site study (other sites included Haiti, India, Indonesia
and Papua New Guinea) that enrolled 26,836 participants 5 years and older.[13] This sample
size is powered to detect serious AEs with a frequency of less than 0.1%. This level of serious
AE detection is recommended by WHO for endorsement of new public health treatments.[35]
The individual sites are not powered for this primary outcome. The sample size of groups in




The total resident population of the two islands was 4610: 1994 in 17 villages on Rotuma and
2616 in 18 villages on Gau (Fig 1, Table 1). The median village size was 108 people, range 18 to
298 (S4 Table). Participants were recruited over a four-month period from July 2017 to
November 2017. The total number consented was 3812 (82.7% enrolment coverage). There
was 80% participation for the villages randomised for DA treatment and 84.1% for those ran-
domized for IDA (85.9% for IDA1 and 82.6% for IDA2). There were 449 people (9.7%)
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temporarily away from their village at the time of the enrolment visit and 349 people (7.6%)
who declined (DA group 10.4%, IDA group 6%, S5 Table). The age and sex distribution of
enrolled participants was similar to the overall population distribution of the two islands (S4
Table). The median height and weight for the 2161 participants aged 18 years and older was
169 cm (IQR 163–175 cm) and 84.7 kg (IQR 72.5–97.7 kg) respectively.
Parasitic infections
Lymphatic filariasis assessments were conducted on 3659 of the eligible 3719 participants aged
2 years and above (98.4%). The reasons for non-testing were: declined blood testing (n = 60);
declined a repeat bleed for smear preparation (n = 11); or smear was unreadable due to techni-
cal difficulties (n = 11). The prevalence of lymphatic filariasis across the two treatment groups
was comparable as measured by detection of CFA (14.1%, 95% CI 11.3–17.5%) and Mf (3.8%,
95% CI 2.6–5.6%, Table 1, S6 Table). The geometric mean Mf density was also similar between
Fig 1. CONSORT flow diagram detailing village cluster randomisation, individual enrolment, treatment received, safety monitoring follow-up and resulting total
including in analyses. DA: diethylcarbamazine and albendazole; IDA1: ivermectin one dose, diethylcarbamazine and albendazole; IDA2: ivermectin two doses,
diethylcarbamazine and albendazole.
https://doi.org/10.1371/journal.pntd.0008106.g001
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groups (DA 239 Mf/ml, range 17–4643, 95% CI 149–383, versus IDA 183 Mf/ml, range 17–
9168, 95% CI 128–260). The intracluster correlation coefficient for Mf was 0.205. Rotuma had
a higher CFA prevalence (24.8% versus Gau 6.1%; risk difference (RD) 19.3%, 95% CI 14.1–
24.5%) and Mf prevalence (6.9% versus 1.6%; RD 5.6%, 95% CI 2.9–8.2%), but a comparable
infection intensity (geometric mean Mf density Rotuma 206 Mf/ml, range 17–9168, 95% CI
148–288, versus Gau 181 Mf/ml, range 17–4492, 95% CI 106–308). Mf prevalence was higher
in males (6% versus females 1.6%; RD 4.4%, 95% CI 2.4–6.3%), and those aged 35–49 years
had the highest Mf prevalence (7.8%, 95% CI 4.9–12.3%). As the CFA score increased, the pro-
portion with a positive test for Mf also significantly increased; 4.8% of grade 1 CFA were posi-
tive for Mf compared to 55.6% of those with CFA scores of 3 (RD 50.6%, 95% CI 41.5–59.6%).
Scabies was evenly distributed across treatment groups with an overall prevalence of 13.5%
(95% CI 10.4–17.3%), and prevalence peaking at 32.9% (95% CI 25.7–41.0%) in the children
aged 5–9 years. It was more common on Gau (16.9%, 95% CI 12.6–22.2%, versus Rotuma
Table 1. Participant demographic characteristics and baseline parasitic infection prevalence by treatment group.
DA IDA Total
n % (95% CI) n % (95% CI) n % (95% CI)
Enrolment Total population 1616 2994 4610
Total consented 1293 80.0 2519 84.1 3812 82.7
Sex Male 673 52.0 (49.7–54.4) 1293 51.3 (49.4–53.2) 1966 51.6 (50.1–53.1)
Female 620 48.0 (45.6–50.3) 1226 48.7 (46.8–50.6) 1846 48.4 (46.9–49.9)
Age (years) Median (IQR) 27 (10–48) 24 (10–46) 25 (10–47)
<2 38 2.9 (2.1–4.0) 55 2.2 (1.5–3.1) 93 2.4 (1.9–3.1)
2–4 80 6.2 (5.3–7.3) 168 6.7 (5.6–7.9) 248 6.5 (5.7–7.4)
5–9 182 14.1 (11.4–17.3) 359 14.3 (12.3–16.5) 541 14.2 (12.6–16.0)
10–14 172 13.3 (10.6–16.6) 359 14.3 (12.2–16.6) 531 13.9 (12.3–15.8)
15–24 134 10.4 (8.2–13.0) 328 13.0 (7.6–21.4) 462 12.1 (8.2–17.5)
25–34 154 11.9 (9.3–15.1) 264 10.5 (9.2–11.9) 418 11.0 (9.7–12.3)
35–49 236 18.3 (15.8–21.0) 449 17.8 (15.5–20.4) 685 18.0 (16.2–19.9)
50–64 207 16.0 (12.7–20.0) 358 14.2 (12.0–16.8) 565 14.8 (13.0–16.9)
�65 90 7.0 (5.8–8.3) 179 7.1 (5.6–8.9) 269 7.1 (6.0–8.3)
LF Total assessed CFA 1239 2420 3659
Total CFA positive 186 15.0 (8.8–24.4) 330 13.6 (10.0–18.3) 516 14.1 (11.3–17.5)
CFA1—weak positive 64 5.2 (3.7–7.2) 107 4.4 (3.2–6.1) 171 4.7 (3.8–5.8)
CFA2—medium positive 59 4.8 (2.4–9.4) 98 4.1 (3.0–5.4) 157 4.3 (3.3–5.5)
CFA3—strong positive 63 5.1 (2.1–11.6) 125 5.2 (3.4–7.8) 188 5.1 (3.6–7.4)
LF Microfilariae positivea 47 3.8 (1.5–9.1) 93 3.9 (2.6–5.8) 140 3.8 (2.6–5.6)
Geometric mean density Mf/ml 239 (149–383) 183 (128–260) 200 (151–264)
Scabies Identifiedb 176 13.6 (7.9–22.4) 337 13.4 (9.9–17.9) 513 13.5 (10.4–17.3)
STH Stool specimen assessed 268 20.7 658 26.1 926 24.3
Positive microscopy 35 13.1 (6.3–25.1) 136 20.7 (13.2–30.9) 171 18.5 (12.7–26.1)
LF Treatmentc 1216 94.0 (92.5–95.3) 2396 95.1 (93.9–96.1) 3612 94.8 (93.9–95.5)
Any follow-up after LF treatment 1216 100 - 2382 99.4 (98.5–99.8) 3598 99.6 (99.0–99.9)
DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; IQR: interquartile range; LF: lymphatic filariasis; CFA: circulating
filarial antigen; STH: soil-transmitted helminths; CI: confidence intervals
a Denominator is equal to total assessed CFA subtracting 22 with smears declined or unreadable (DA N = 1238, IDA N = 2399, Total N = 3637).
b Denominator is equal to total consented for each group.
c Denominator is equal to total consented for each group. Participants received treatment as randomised except 1 in DA received IDA, 123 in IDA received DA.
https://doi.org/10.1371/journal.pntd.0008106.t001
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8.8%, 95% CI 5.6–13.7%, RD 8.5%, 95% CI 2.7–14.4%) and in females (15% versus males 12%,
RD 3.0%, 95% CI 1.1–4.9%). The STH prevalence was higher in the IDA groups (20.7%, 95%
CI 13.2–30.9%) compared to the DA group (13.1%, 95% CI 6.3–25.1%, RD 5.3%, 95% CI
0–10.5%). Gau had a higher STH prevalence (25.7%, 95% CI 16.9–37.0%, versus Rotuma 5.0%,
95% CI 2.8–8.8%, RD 20.1%, 95% CI 10.8–29.5%), as did males (23.5%, 95% CI 17.1–31.6%,
versus females 13.8%, 95% CI 8.2–22.2%, RD 10.9%, 95%CI 5.3–16.4%). Children aged 10–14
years had the highest STH prevalence (30.1%, 95% CI 13.3–54.6%).
One infection (either filariasis, scabies or STH), was identified in 1136 participants (29.8%
of enrolled). Sixty-one participants had two infections identified and three participants were
co-infected with all three.
Treatment
A majority of participants were eligible and received filariasis treatment according to the
assignment of their village (94% and 95.1% in DA and IDA groups respectively). One person
in the DA group received IDA and 123 in the IDA group received DA (due to exclusion from
ivermectin because of weight and/or age). Thirty-two of the 305 (10.5%) participants with sca-
bies in the IDA group were ineligible for ivermectin and received permethrin instead on day 0.
The 164 participants with scabies in the DA group did not receive permethrin treatment until
day 8, after safety monitoring period was completed. Applying intention to treat principles, we
included these individuals for analysis in their village randomisation groups and not by the
individual treatment they received.
Adverse events
Of the 3612 participants who received MDA, 14 (0.4%) were lost to follow-up during the 7-day
safety monitoring period following treatment (Fig 1). One participant was not seen during the
two-day active monitoring period but presented to the study nurse for review on day 5.
One or more AE was reported by 600 (16.7%) participants (Table 2, S6 Table), with symp-
toms first starting during the active monitoring period for 92.7%. AE rates did not differ by
treatment group, and similar AE frequencies were reported after the two treatments in males
(DA 15.9% versus IDA 15.1%, P = 0.80) and in persons with microfilaremia (DA 45.7% versus
IDA 41.9%, P = 0.34). Participants found to have scabies on examination reported AEs less fre-
quently than those without (14.3% vs 17.0%, P = 0.24). This difference was most marked in the
DA group (12.2% AEs in participants with scabies versus 17.4% without scabies, P = 0.04)
compared to the IDA group (15.4% with scabies versus 16.9% without, P = 0.67). There were
121 children aged less than 5 years in the IDA group that received DA and permethrin and
were followed up. Of these, six (5.0%) experienced an AE. There were 32 that had scabies and
two (6.3%) experienced an AE. In contrast, there were 56 children aged less than 5 years in the
DA group that received DA and were followed up. Six (10.7%) experienced an AE. None of the
12 participants with scabies in this sub-group reported an AE, noting that they also did not
receive scabies directed treatment until day 8. We found a similar difference in AE reporting
based on STH results (13.9% AEs with STH positive stool versus 18.4% STH negative,
P = 0.13). We observed a similar frequency of AEs when we excluded children aged less than 5
years (DA 17.0% versus IDA 17.3%, P = 0.90).
The type and severity of AEs was similar across treatment groups (Fig 2, S7 Table). Fatigue
was the most common AE with 307 (51.2%) of participants who experienced an AE reporting
this symptom. Of reported events, 93.2% were graded as mild, 5.5% moderate and 1.3% severe.
Symptoms reported as severe by 8 participants (0.2% of participants treated and followed up)
were fatigue, headache, dizziness, myalgia, diarrhoea, rash, dyspnoea and chills. There was no
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life-threatening AE in either treatment group. Eighteen (3.2%) had an AE that persisted
beyond 48 hrs following treatment and 44 (7.3%) experienced their first AE after 48 hrs. Only
two participants had persistent AEs with severity greater than mild by day 7 after treatment.
In the 139 participants with microfilaremia that were treated, arthralgia (n = 8, 17.4%) and
fatigue (n = 7, 15.2%) were the most common symptoms experienced in the DA group.
Whereas fatigue (n = 23, 24.7%), arthralgia (n = 13, 14.0%), and muscle weakness (n = 12,
12.9%) were the most common in the IDA group. Fever and scrotal pain, two other commonly
reported symptoms following filariasis treatment in the presence of microfilaremia, were
reported in 2.9% (n = 3, 6.5% in DA and n = 1, 1.1% in IDA group, P = 0.11) and 2.2% (equal
in both groups) respectively. There was only one participant in each treatment group with a
severe AE. In a post-hoc analysis of participants with microfilaremia, the geometric mean Mf
density was significantly higher in those that experienced an AE after treatment (357 Mf/ml,
95% CI 223–569 versus 131 Mf/ml, 95% CI 95–181, ttest P = 0.0004).
Table 2. Frequency of adverse events by treatment group.
DA IDA Total
N n % N n % N n %
Any AE Total treated LF and followed upb 1216 203 16.7 2382 397 16.7 3598 600 16.7
Island Rotuma 412 55 13.3 1152 203 17.6 1564 258 16.5
Gau 804 148 18.4 1230 194 15.8 2034 342 16.8
Sex Male 642 102 15.9 1241 188 15.1 1883 290 15.4
Female 574 101 17.6 1141 209 18.3 1715 310 18.1
Age (years) Reported AE median (IQR) 41 (19.5–55) 33 (15–49) 36 (16–51.5)
2–4 56 6 10.7 123 6 4.9 179 12 6.7
5–9 181 22 12.2 356 36 10.1 537 58 10.8
10–14 172 13 7.6 358 48 13.4 530 61 11.5
15–24 132 17 12.9 322 60 18.6 454 77 17.0
25–34 146 27 18.5 247 53 21.5 393 80 20.4
35–49 235 50 21.3 442 96 21.7 677 146 21.6
50–64 206 50 24.3 358 69 19.3 564 119 21.1
�65 88 18 20.5 176 29 16.5 264 47 17.8
LFa CFA negative 1030 155 15.0 2035 307 15.1 3065 462 15.1
Total CFA positive 184 48 26.1 328 89 27.1 512 137 26.8
CFA1—weak positive 63 14 22.2 107 22 20.6 170 36 21.2
CFA2—medium positive 59 15 25.4 97 25 25.8 156 40 25.6
CFA3—strong positive 62 19 30.6 124 42 33.9 186 61 32.8
LF Microfilariae negative 1167 182 15.6 2249 354 15.7 3416 536 15.7
Microfilariae positive 46 21 45.7 93 39 41.9 139 60 43.2
Scabies Not identified 1052 183 17.4 2077 350 16.9 3129 533 17.0
Identified 164 20 12.2 305 47 15.4 469 67 14.3
STH Negative microscopy 226 40 17.7 504 94 18.7 730 134 18.4
Positive microscopy 35 5 14.3 131 18 13.7 166 23 13.9
DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; AE: adverse event; IQR: interquartile range; LF: lymphatic filariasis;
CFA: circulating filarial antigen; STH: soil-transmitted helminths.
a Total assessed for LF CFA N = 3577 (2 in DA and 19 in IDA weren’t assessed for LF).
b Participants received treatment as randomised except 1 in DA village received IDA, and 121 in IDA villages received DA (ineligible for ivermectin due to weight and/
or age).
https://doi.org/10.1371/journal.pntd.0008106.t002
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In the 469 participants with scabies that were treated for filariasis, 67 (14.3%) reported an
AE, and a higher proportion were in the IDA group (n = 47, 15.4% versus DA n = 20, 12.2%,
P = 0.61). In this scabies sub-group, fatigue remained the most common symptom (DA n = 10,
6.1% versus IDA n = 23, 7.5%, P = 0.71). Abdominal pain was reported more in both treatment
groups with scabies (DA n = 2, 1.2% and IDA n = 3, 1.0%) compared to all participants
(n = 18, 0.5%, P = 0.22). In the IDA group with scabies compared to the whole cohort, there
was notable increased reporting of pruritus (n = 7, 2.3% versus n = 36, 1.0%, P = 0.046 respec-
tively) and rash (n = 5, 1.6% versus n = 15, 0.4%, P = 0.016 respectively). Only one participant
who reported pruritus in the IDA group received permethrin.
An STH infection was identified in 166 participants and AEs were reported by 23 (13.9%).
Gastrointestinal symptoms (nausea, vomiting, diarrhoea, abdominal pain, and abdominal dis-
tension) were reported less by members of this sub-group than overall (STH positive DA 0%
versus IDA n = 5, 3.8%, versus overall n = 153, 4.3%).
Serious adverse events
There were three serious AE reports. One participant who received DA, had dizziness and
hypertension requiring overnight hospitalization, six days after treatment, and another in the
DA group had an acute exacerbation of chronic obstructive pulmonary disease requiring hos-
pitalization, two days after treatment. One participant with pre-existing lower limb lymphoe-
dema developed cellulitis of the limb five days after IDA treatment. This participant
experienced severe limitation of mobility and personal activities of daily living, but did not
require hospitalization. All three had complete resolution of their symptoms.
Fig 2. Type, frequency and severity of adverse event symptoms by treatment group, reported as a percentage of total number of participants treated and
followed up. DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; AE: adverse event. a Denominator total treated
and followed up N = 3598.
https://doi.org/10.1371/journal.pntd.0008106.g002
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Risk factors for adverse events
Univariate and multivariate analyses revealed no difference in reporting of AEs between treat-
ment groups or by island locations (Table 3). Participants aged 50–64 years of age had the
highest risk of an AE (adjusted RD 12.5%, 95% CI 5.4–19.6%). We observed a linear relation-
ship between baseline filarial infection status of participants and AE reporting, with 15.1% of
participants having a negative CFA test reporting an AE compared to 33.1% of those with a
grade 3 CFA test (RD 19.4%, 95% CI 10.5–28.4%). Further, 43.2% of participants with Mf
reported an AE compared to 15.8% of those without Mf (adjusted RD 26.4%, 95% CI 18.5–
34.3%). Males reported fewer AEs (15.4%) than females (18.1%, adjusted RD 3.5%, 95% CI
0.9–6.1%), despite having a much higher Mf prevalence (6% versus 1.6%). There was no
increased risk of reporting of AEs in participants with scabies or STH (Tables 2 and 3).
Discussion
Our study demonstrates that community MDA with IDA has a similar AE profile to the tradi-
tional DA combination in Fiji. Approximately one in every six individuals treated experienced
an AE, but the vast majority of these events were mild and resolved within seven days. Fatigue,
headache, dizziness, nausea and arthralgia were the five most common symptoms reported.
The type of AEs in our study were consistent with those reported in previous studies.[8, 13,
36]
The safety of IDA has been demonstrated in small randomised trials[8, 10], and now in a
large multi-site community safety trial that included Fiji.[13] However, these studies have not
reported on the effect of scabies and STH infections on the reporting of AEs. The Fiji results
we report here, clearly outline the community prevalence of each neglected tropical disease
and their relationship to reporting of AEs following IDA compared to DA. Despite a high bur-
den of scabies and STH there was no increased reporting of AEs in persons with these
infections.
As expected, we observed a strong positive relationship between markers of filarial infection
and the frequency of AEs.[11] This was most prominent among participants with microfilare-
mia detected by the 60 μl smear. However, it was also observed in participants who were CFA
positive without microfilaremia. Since most AEs are attributed to death of Mf [11], it is possi-
ble that these participants had low density microfilaremia that was not detected by smear, or
Mf were not circulating at the time of testing. This uncertainty around presence of Mf might
have been avoided if we used the more sensitive method of membrane filtration with 1ml
venous blood, but this is not practical for large numbers in this study.[37] We observed fever
in participants with microfilaremia less frequently than expected from the smaller safety trials.
[8–10] This may have been due to reduced intensity of monitoring in our study and the
absence of other febrile infectious syndromes including malaria. We noted that women were
more likely to report an AE despite being less likely to have microfilaremia. This gender differ-
ence has been reported in other studies [10, 13], and is hypothesised to be because women are
more likely to report subjective AEs than men.
There are a number of strengths to our study. First, the randomisation of villages achieved
balance of treatment groups with regard to baseline demographic characteristics, prevalence of
filariasis and scabies, numbers of people treated and monitored for AEs. Second, we main-
tained high participation over 7 days of safety monitoring, with only 14 participants lost to fol-
low-up. It is unlikely that these participants experienced a severe or serious AE that went
undetected due to the close proximity of the study team to the local health care providers.
Our study was limited by the inability to blind participants and assessors to the treatment
group. In a safety study of this kind, blinding would have been ideal, but was not feasible,
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largely because of the addition of a topical treatment to the intervention, as well as the logistics
of providing a second dose to all participants. A further limitation of the study is the relatively
small number of participants in our sub-analyses, meaning that cautious interpretation is
required for risk differences.
Current modelling suggests that MDA coverage above 65% is required for success of the
strategy to interrupt transmission.[38, 39] After more than 10 rounds of MDA for filariasis in
the study sites, the risk of participation fatigue increases and therefore likelihood of high MDA
coverage decreases.[40, 41] Comprehensive community engagement is recognised as crucial
for success of the introduction of the new IDA strategy.[14] In our experience, highlighting
the action of the IDA MDA on the three common infections found at our study sites prior to
enrolment, assisted in our high population coverage for MDA. This message can now be cou-
pled with the findings of the study that the combination of the three drugs for MDA is safe.
Our study describes the large burden of neglected tropical diseases in Fiji that may benefit
from IDA. Our results confirm that introducing MDA using IDA as an elimination strategy
for lymphatic filariasis in Fiji is as safe as the current DA combination that has been imple-
mented and accepted by communities since 2002. Our results provide confidence for the safety
Table 3. Risk factor analysis for occurrence of adverse events.
Totala Univariate analysisa Multivariate analysisa,b
Factor N n % RD % (95% CI) RD % (95% CI)
Treatment DA 1213 203 16.7 Ref Ref
IDA 2342 393 16.8 0.1 (-5.2 to 5.4) 0.4 (-4.8 to 5.5)
Island Rotuma 1525 254 16.7 Ref Ref
Gau 2030 342 16.8 0.2 (-4.9 to 5.3) 1.5 (-3.4 to 6.4)
Gender Male 1853 286 15.4 Ref Ref
Female 1702 310 18.2 2.8 (-0.1 to 5.7) 3.5 (0.9 to 6.1)
Age (years) 2–4 156 11 7.1 Ref Ref
5–9 537 58 10.8 3.7 (-0.5 to 7.8) 3.2 (-1.5 to 7.9)
10–14 526 61 11.6 4.5 (-0.1 to 9.1) 4.5 (-0.3 to 9.3)
15–24 453 77 17.0 9.9 (4.1 to 15.7) 9.7 (3.6 to 15.9)
25–34 393 80 20.4 13.2 (8 to 18.5) 11.9 (6.5 to 17.3)
35–49 671 143 21.3 14.2 (9.7 to 18.7) 11.7 (6.5 to 17)
50–64 557 119 21.4 14.3 (7.9 to 20.7) 12.5 (5.4 to 19.6)
�65 262 47 17.9 10.8 (5.1 to 16.6) 9.1 2.7 to 15.4)
LF Total CFA negative 3065 462 15.1 Ref - -
Total CFA positive 490 134 27.3 13.4 (7.8 to 19.1) - -
CFA1—weak positive 165 35 21.2 7 (-0.4 to 14.3) - -
CFA2—medium positive 147 40 27.2 13.4 (5.1 to 21.8) - -
CFA3—strong positive 178 59 33.1 19.4 (10.5 to 28.4) - -
LF Microfilariae positive 139 60 43.2 28.2 (20.6 to 35.7) 26.4 (18.5 to 34.3)
Scabies Identified 461 67 14.5 -2.6 (-7 to 1.8) 1.3 (-2.8 to 5.5)
STHc Positive microscopy 165 23 13.9 -4.9 (-10.6 to 0.8) - -
RD: risk difference; CI: confidence interval; Ref: reference group; DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; LF:
lymphatic filariasis; CFA: circulating filarial antigen; STH: soil-transmitted helminths.
a Denominator for total, univariate and multivariate analyses’ N = 3555 (excluded 21 declined CFA testing, 11 unreadable Mf smears, 11 declined Mf smears).
b Multivariate risk difference analysis excludes CFA scores and STH results.
c Denominator for STH analysis N = 881.
https://doi.org/10.1371/journal.pntd.0008106.t003
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of IDA within other Pacific populations where lymphatic filariasis remains endemic, along
with scabies and soil-transmitted helminths.
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